Skip to main content

Table 5 Pairwise league table of MACE and HHF

From: Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease

Comparisons for MACE (bottom left) of the 11 interventions and HHF (upper right) of the 8 interventions. RR with 95% CI

EM

1.01 (0.65,1.59)

0.94 (0.57,1.55)

0.85 (0.49,1.50)

1.12 (0.71,1.78)

1.33 (0.87,2.03)

 

1.85 (1.14,3.01)

 

1.24 (0.76,2.00)

 

1.68 (1.14,2.50)

1.14 (0.88,1.49)

CA

0.93 (0.64,1.35)

0.84 (0.53,1.33)

1.11 (0.80,1.53)

1.31 (1.00,1.71)

 

1.83 (1.28,2.61)

 

1.22 (0.86,1.74)

 

1.66 (1.34,2.06)

0.96 (0.72,1.29)

0.84 (0.67,1.06)

DA

0.91 (0.55,1.51)

1.19 (0.81,1.76)

1.41 (1.00,2.00)

 

1.97 (1.30,2.99)

 

1.31 (0.87,1.99)

 

1.79 (1.32,2.44)

0.81 (0.59,1.13)

0.71 (0.54,0.93)

0.84 (0.63,1.13)

ER

1.32 (0.82,2.10)

1.55 (1.01,2.39)

 

2.17 (1.33,3.54)

 

1.45 (0.89,2.36)

 

1.97 (1.32,2.95)

1.17 (0.90,1.53)

1.02 (0.85,1.24)

1.22 (0.97,1.52)

1.44 (1.10,1.89)

SO

1.18 (0.89,1.58)

 

1.65 (1.14,2.39)

 

1.10 (0.76,1.59)

 

1.50 (1.18,1.91)

1.01 (0.79,1.29)

0.88 (0.75,1.04)

1.05 (0.85,1.29)

1.24 (0.96,1.60)

0.86 (0.73,1.02)

FI

 

1.40 (1.01,1.93)

 

0.93 (0.68,1.29)

 

1.27 (1.08,1.49)

0.96 (0.69,1.33)

0.84 (0.64,1.10)

1.00 (0.74,1.34)

1.18 (0.85,1.65)

0.82 (0.62,1.07)

0.95 (0.73,1.23)

AL

     

0.86 (0.66,1.13)

0.75 (0.62,0.92)

0.89 (0.71,1.13)

1.06 (0.80,1.40)

0.74 (0.60,0.90)

0.85 (0.71,1.02)

0.90 (0.68,1.19)

EX

 

0.67 (0.45,0.99)

 

0.91 (0.69,1.21)

1.08 (0.73,1.58)

0.94 (0.67,1.32)

1.12 (0.78,1.60)

1.32 (0.89,1.96)

0.92 (0.65,1.29)

1.06 (0.77,1.48)

1.12 (0.76,1.66)

1.25 (0.88,1.77)

SE

   

1.29 (0.97,1.72)

1.13 (0.90,1.41)

1.34 (1.04,1.73)

1.59 (1.18,2.13)

1.10 (0.88,1.38)

1.28 (1.04,1.56)

1.35 (1.00,1.81)

1.50 (1.19,1.89)

1.20 (0.84,1.72)

LI

 

1.14 (0.93,1.41)

1.27 (0.88,1.82)

1.11 (0.81,1.51)

1.31 (0.94,1.84)

1.56 (1.08,2.25)

1.08 (0.79,1.48)

1.25 (0.93,1.69)

1.32 (0.91,1.91)

1.47 (1.07,2.02)

1.18 (0.77,1.80)

0.98 (0.70,1.37)

EF

 

0.89 (0.71,1.12)

0.78 (0.68,0.89)

0.92 (0.77,1.11)

1.09 (0.87,1.38)

0.76 (0.66,0.87)

0.88 (0.80,0.97)

0.93 (0.73,1.18)

1.03 (0.89,1.20)

0.83 (0.60,1.13)

0.69 (0.58,0.82)

0.70 (0.53,0.93)

PL

  1. RR with 95% CI
  2. EM, empagliflozin; CA, canagliflozin; DA, dapagliflozin; ER, ertugliflozin; SO, sotagliflozin; FI, finerenone; AL, albiglutide; EX, exenatide; SE, semaglutide; LI, liraglutide; EF, efpeglenatide; PL, placebo
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840